Abstract
Gestational diabetes mellitus (GDM) and pre-gestational diabetes are known to pose risks to the mother and developing fetus, often related to abnormal fetal growth. One potential mediator of maternal effects on fetal growth is Placental Growth Hormone (PGH). PGH is produced by the syncytiotrophoblast and found predominantly in the maternal circulation. It progressively replaces pituitary growth hormone (hGH) in the human maternal circulation from midgestation onwards, peaking towards term. PGH appears to be an important potential regulator of maternal insulin resistance in human pregnancy and may influence fetal growth both by modifying substrate availability and through paracrine actions in the placental bed. The details of PGH regulation remain relatively poorly understood, but current evidence does suggest a central role in growth restricted pregnancies. There is currently less evidence of a pathophysiologic role in production of the macrosomic fetal phenotype commonly seen in response to hyperglycaemia, although our recent in vitro studies do raise the possibility of feto-placental feedback as a mechanism of growth modulation.
Keywords: Placental growth hormone, Insulin-like Growth Factor-1, Diabetes, Pregnancy, Fetal growth, Insulin resistance
Current Diabetes Reviews
Title: Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Volume: 5 Issue: 3
Author(s): H. D. McIntyre, W. Zeck and A. Russell
Affiliation:
Keywords: Placental growth hormone, Insulin-like Growth Factor-1, Diabetes, Pregnancy, Fetal growth, Insulin resistance
Abstract: Gestational diabetes mellitus (GDM) and pre-gestational diabetes are known to pose risks to the mother and developing fetus, often related to abnormal fetal growth. One potential mediator of maternal effects on fetal growth is Placental Growth Hormone (PGH). PGH is produced by the syncytiotrophoblast and found predominantly in the maternal circulation. It progressively replaces pituitary growth hormone (hGH) in the human maternal circulation from midgestation onwards, peaking towards term. PGH appears to be an important potential regulator of maternal insulin resistance in human pregnancy and may influence fetal growth both by modifying substrate availability and through paracrine actions in the placental bed. The details of PGH regulation remain relatively poorly understood, but current evidence does suggest a central role in growth restricted pregnancies. There is currently less evidence of a pathophysiologic role in production of the macrosomic fetal phenotype commonly seen in response to hyperglycaemia, although our recent in vitro studies do raise the possibility of feto-placental feedback as a mechanism of growth modulation.
Export Options
About this article
Cite this article as:
McIntyre D. H., Zeck W. and Russell A., Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy, Current Diabetes Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339909788920947
DOI https://dx.doi.org/10.2174/157339909788920947 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Placental Transport of Folate and Thiamine: A Mini-Review
Current Women`s Health Reviews Antidiabetic Potential of Silver/Chitosan/Ascorbic Acid Nanocomposites
Current Nanomedicine Endothelial Extracellular Vesicles Produced by Senescent Cells: Pathophysiological Role in the Cardiovascular Disease Associated with all Types of Diabetes Mellitus
Current Vascular Pharmacology Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus
Current Diabetes Reviews Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Glucocorticoids in Pregnancy
Current Pharmaceutical Biotechnology Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Comparison of Amniotic Fluid Index and Single Deepest Vertical Pocket
Current Women`s Health Reviews Diabetic Medications in Pregnancy
Current Diabetes Reviews